Canine indolent and aggressive lymphoma: Clinical spectrum with histologic correlation

Veterinary and Comparative Oncology

Volumn 13, Issue 4, 2015, Pages 348-362

  Aresu, L ^a   Martini, V ^b   Rossi, F ^c   Vignoli, M ^d   Sampaolo, M ^c   Arico A ^a   Laganga, P ^c   Pierini, A ^c   Frayssinet, P ^e   Mantovani, R ^a   Marconato, L ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Clinica Veterinaria dell'Orologio and Centra Oncologico Veterinario   (Italy)

^d Clinica Veterinaria dell'Orologio   (Italy)

^e Urodelia   (France)

Author keywords

Clinical stage; Dog; Histological subtype; Lymphoma

Indexed keywords

LACTATE DEHYDROGENASE;

ANIMAL; BLOOD; CANCER STAGING; DOG; DOG DISEASES; FEMALE; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; VETERINARY;

ANIMALS; DOG DISEASES; DOGS; FEMALE; L-LACTATE DEHYDROGENASE; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; NEOPLASM STAGING; PROGNOSIS;

EID: 84944278894     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12048     Document Type: Article

References (37)

1. Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML and Fournel-Fleury C. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 2010; 47: 414-433.
2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B and Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA and Armitage JO. Lymphoma classification-the gap between biology and clinical management is closing. Blood 1996; 88: 4085-4089.
4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting. Airlie House. Virginia, November 1997. Annals of Oncology 1999; 10: 1419-1432.
5. Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F, Durham A, Ehrhart EJ, Johnson Y, Jones C, Kiupel M, Labelle P, Lester S, Miller M, Moore P, Moroff S, Roccabianca P, Ramos-Vara J, Ross A, Scase T, Tvedten H and Vernau W. Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology 2011; 48: 198-211.
6. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K and Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. The Veterinary Journal 2004; 167: 158-166.
7. Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. The Veterinary Journal 2011; 188: 34-38.
8. Valli VE, Vernau W, de Lorimier LP, Graham PS and Moore PF. Canine indolent nodular lymphoma. Veterinary Pathology 2006; 43: 241-256.
9. Stefanello D, Valenti P, Zini E, Comazzi S, Gelain ME, Roccabianca P, Avallone G, Caniatti M and Marconato L. Splenic marginal zone lymphoma in 5 dogs (2001-2008). Journal of Veterinary Internal Medicine 2011; 25: 90-93.
10. Flood-Knapik KE, Durham AC, Gregor TP, Sanchez MD, Durney ME and Sorenmo KU. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Veterinary and Comparative Oncology 2012. doi:10.1111/j.1476-5829.2011.00317.x.
11. Valli VE, Kass PH, Myint MS and Scott F. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Veterinary Pathology 2013. doi:10.1177/0300985813478210.
12. Flory AB, Rassnick KM, Stokol T, Scrivani PV and Erb HN. Stage migration in dogs with lymphoma. Journal of Veterinary Internal Medicine 2007; 21: 1041-1047.
13. Vail DM, Michels GM, Khanna C, Selting KA, London CA and and the Veterinary Cooperative Oncology Group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2010; 8: 28-37.
14. Regan RC, Kaplan MS and Bailey DB. Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians. Veterinary and Comparative Oncology 2012. doi:10.1111/j.1476-5829.2012.00318.x.
15. Gelain ME, Mazzilli M, Riondato F, Marconato L and Comazzi S. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. Veterinary Immunology and Immunopathology 2008; 121: 179-188.
16. st edn., World Health Organization, Geneva, 1980: 46-47.
17. Teske E, Wisman P, Moore PF and Van Heerde P. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology. Experimental Hematology 1994; 22: 1179-1187.
18. Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, Scott MC, Valli VEO, Lindblad-Toh K, Burgess KE, Husbands BD, Henson MS, Borgatti A, Kisseberth WC, Hunter LE, Breen M, O'Brien TD and Modiano JF. Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphomas. Veterinary Pathology 2013. doi:10.1177/0300985812465325.
19. Martini V, Melzi E, Comazzi S and Gelain ME. Peripheral blood abnormalities and bone marrow infiltration in canine large B cell lymphoma: is there a link? Veterinary and Comparative Oncology 2013. doi:10.1111/vco.12024.
20. Savage KJ. Therapies for peripheral T-cell lymphomas. Hematology/the Education Program of the American Society of Hematology 2011; 2011: 515-524.
21. Milanovic N, Matkovic S, Ristic D, Jelic S and Petrovic M. Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. Journal of the Balkan Union of Oncology 2012; 17: 497-501.
22. Huff CA, Matsui W, Smith BD and Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006; 107: 431-434.
23. Chiappella A, Ciochetto C, Orsucci L and Vitolo U. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM). Clinical Lymphoma, Myeloma and Leukemia 2011; 11: 149-151.
24. Piccaluga PP, Sapienza MR, Agostinelli C, Sagramoso C, Mannu C, Sabattini E, Zinzani PL and Pileri SA. Biology and treatment of follicular lymphoma. Expert Review of Hematology 2009; 2: 533-547.
25. Landgren O and Tilly H. Epidemiology, pathology and treatment of non-follicular indolent lymphomas. Leukemia and Lymphoma 2008; 49: 35-42.
26. Zemann BI, Moore AS, Rand WM, Mason G, Ruslander DM, Frimberger AE, Wood CA, L'Heureux DA, Gliatto J and Cotter SM. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. Journal of Veterinary Internal Medicine 1998; 12: 465-470.
27. Simon D, Moreno SN, Hirschberger J, Moritz A, Kohn B, Neumann S, Jurina K, Scharvogel S, Schwedes C, Reinacher M, Beyerbach M and Nolte I. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. Journal of the American Veterinary Medical Association 2008; 232: 879-885.
28. Lurie DM, Gordon IK, Théon AP, Rodriguez CO, Suter SE and Kent MS. Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma. Journal of Veterinary Internal Medicine 2009; 23: 1064-1070.
29. Marconato L, Stefanello D, Valenti P, Bonfanti U, Comazzi S, Roccabianca P, Caniatti M, Romanelli G, Massari F and Zini E. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. Journal of the American Veterinary Medical Association 2011; 238: 480-485.
30. Kimby E. Management of advanced-stage peripheral T-cell lymphomas. Current Hematologic Malignancy Reports 2007; 2: 242-248.
31. th edn., St Louis, Saunders Elseviers, 2012: 608-638.
32. Beaver LM, Strottner G and Klein MK. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008). Journal of the American Veterinary Medical Association 2010; 237: 1052-1055.
33. Morabito F, Baldini L, Stelitano C, Luminari S, Frassoldati A, Merli F, Colombi M, Sabbatini R, Brugiatelli M, Federico M and Gruppo Italiano per lo studio dei linfomi. Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy. Leukemia and Lymphoma 2002; 43: 1933-1938.
34. Luminari S and Federico M. Prognosis of follicular lymphomas. Hematological Oncology 2006; 24: 64-72.
35. Solal-Céligny P, Cahu X and Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? International Journal of Hematology 2010; 92: 246-254.
36. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP and Fisher RI. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. Journal of Clinical Oncology 1993; 11: 644-651.
37. Bendandi M, Pileri SA and Zinzani PL. Challenging paradigms in lymphoma treatment. Annals of Oncology 2004; 15: 703-711.